TRANSGENE (EPA:TNG) | WebDisclosure

Basculer en Français

10826	Companies
234868	Keywords
163739	Articles
125718	Press releases

Home
Companies
TRANSGENE

PRESS RELEASE

published on 03/27/2025 at 17:45, 1 year 4 months ago

Transgene franchit des étapes clés en 2024, avec la preuve de principe clinique de son vaccin individualisé contre le cancer ? Perspectives prometteuses pour 2025
Transgene publie ses résultats annuels 2024 et fait le point sur son activité, notamment la preuve de principe clinique de son vaccin individualisé contre le cancer. Perspectives prometteuses pour 2025

Résultats Annuels Perspectives Cancer Transgene Vaccin Thérapeutique
PRESS RELEASE

published on 03/27/2025 at 17:45, 1 year 4 months ago

Transgene Achieves Key Milestones in 2024, Including Clinical Proof of Principle for Individualized Cancer Vaccine ? Strong Outlook for 2025
Transgene achieves key milestones in 2024, including clinical proof of principle for individualized cancer vaccine TG4050, with strong outlook for 2025. New trial planned in Q4 2025 for a second indication

Milestones Cancer Vaccine Transgene 2025 Outlook Clinical Proof
BRIEF

published on 01/21/2025 at 17:50, 1 year 6 months ago

Transgene se prépare pour le Biomed Forum des investisseurs

Investisseurs BIOMED Forum Immunothérapie Transgene Vecteurs Viraux
BRIEF

published on 01/21/2025 at 17:50, 1 year 6 months ago

Transgene Prepares for Biomed Investor Forum

Investors BIOMED Forum Immunotherapy Transgene Viral Vectors
PRESS RELEASE

published on 01/21/2025 at 17:45, 1 year 6 months ago

Transgene participera à la conférence investisseurs Biomed Forum
Transgene participera à la conférence investisseurs Biomed Forum le 4 février 2025. Présentation de ses immunothérapies contre le cancer reposant sur des vecteurs viraux

BIOMED Forum Immunothérapie Cancer Transgene Vecteurs Viraux
PRESS RELEASE

published on 01/21/2025 at 17:45, 1 year 6 months ago

Transgene to Participate in the Biomed Forum Investor Conference
Transgene's management team to participate in the Biomed Forum Investor Conference in Paris on February 4, 2025

Investor Conference Paris BIOMED Forum Transgene February 4
BRIEF

published on 11/05/2024 at 07:35, 1 year 9 months ago

Transgene et ProBioGen unissent leurs forces pour les vaccins anti-cancer personnalisés

Biotechnologie Cancer Transgene ProBioGen Vaccins Personnalisés
BRIEF

published on 11/05/2024 at 07:35, 1 year 9 months ago

Transgene and ProBioGen join forces for personalized cancer vaccines

Biotechnology Cancer Transgene ProBioGen Personalized Vaccines
PRESS RELEASE

published on 11/05/2024 at 07:30, 1 year 9 months ago

Transgene et ProBioGen collaborent pour faire progresser le développement des vaccins thérapeutiques individualisés
Transgene et ProBioGen collaborent pour développer les vaccins thérapeutiques individualisés, annoncent un accord de licence pour la lignée cellulaire AGE1.CR.pIX®

Transgene Vaccins ProBioGen Thérapeutiques Lignée Cellulaire
PRESS RELEASE

published on 10/14/2024 at 07:30, 1 year 9 months ago

Transgene Provides Update on Phase II Trial of Therapeutic Cancer Vaccine TG4001 in Recurrent or Metastatic HPV16-Positive Cervical and Anogenital Cancers

Accesswire

Published on 08/12/2026 at 15:42, 4 hours 7 minutes ago

Critical Elements 10,000-Meter Summer Drill Program at Rose West Resumes with Positive Results
Published on 08/12/2026 at 15:42, 4 hours 7 minutes ago

Critical Elements redémarre son programme de forage estival de 10 000 mètres à Rose Ouest avec des résultats positifs
Published on 08/12/2026 at 15:00, 4 hours 49 minutes ago

Karbon-X and Core Energy Sign Letter of Intent to Explore Commercial EV Charging Infrastructure in South America
Published on 08/12/2026 at 14:45, 5 hours 4 minutes ago

Lobe Sciences Ltd. Announces Non-Brokered Private Placement
Published on 08/12/2026 at 14:30, 5 hours 19 minutes ago

Recent Corporate Events Recap

View all ACCESSWIRE

EQS Group

Published on 08/12/2026 at 19:37, 11 minutes ago

EQS-Adhoc: Brockhaus Technologies AG: Preliminary revenue for H1 2026 at €13.4 million and adjusted EBITDA at €-0.5 million; forecast for the continuing operations unchanged
Published on 08/12/2026 at 18:50, 58 minutes ago

Holding(s) in Company
Published on 08/12/2026 at 18:29, 1 hour 19 minutes ago

Designated Persons Notifications
Published on 08/12/2026 at 18:29, 1 hour 19 minutes ago

Designated Persons Notifications
Published on 08/12/2026 at 18:17, 1 hour 31 minutes ago

EQS-Adhoc: Gateway Real Estate AG resolves segment change from the regulated market (Prime Standard) to the Scale segment of the open market (Freiverkehr) on the Frankfurt Stock Exchange

Les Echos

Published on 08/11/2026 at 17:45, 1 day 2 hours ago

DAMARTEX / Droits de vote bruts et réels au 31 juillet 2026
Published on 08/11/2026 at 17:40, 1 day 2 hours ago

Infotel : Déclaration des transactions sur actions propres réalisées du 3 au 7 août 2026 dans le cadre du programme de rachat d’actions
Published on 08/10/2026 at 18:00, 2 days 1 hour ago

AXA: Information relating to the number of voting rights and shares making up the share capital on 31/07/2026
Published on 08/10/2026 at 18:00, 2 days 1 hour ago

AXA : Information relative au nombre total de droits de vote et d'actions composant le capital social au 31/07/2026
Published on 08/10/2026 at 17:45, 2 days 2 hours ago

Weekly share buyback

View all LES ECHOS COMFI WIRE